Therapeutic Potential of Stem Cell Conditioned Medium on Chronic Ulcer Wounds
Status:
Completed
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
Chronic wounds (CW) still represents a heavy burden to many patients and health care
institution. Despite the most recent advances in wound management, up to 50% of chronic
wounds still fail to heal. Conventional treatment of chronic wounds does not seem to work in
several cases, consumes enormous amount of money and time, so it is necessary to develop
different strategies. Previous studies have reported stem cells ability in tissue
regenerations due mainly to its secreted paracrine factors, rather than its differentiation
ability to become new cells. The factors is called secretomes, microvesicles, or exosomes,
that can be found in the medium where the cells are growing, therefore it called conditioned
medium (CM). Mesenchymal stem cells (MSCs) such as Wharton's Jelly Mesenchymal Stem Cells
(WJ-MSC) appear to emerge as a promising wound healing therapy. To the best of investigator's
knowledge, after conducted a pilot study using animal model to gain the preliminary data for
the ulcer healing potential, this is the investigator's first clinical study to see the
therapeutic potentials of Conditioned Medium Stem Cell as an additional growth factors in
chronic skin ulcer healing and to compare the success of chronic ulcer healing in patients
undergoing CM treatment and standard approach. The investigators will examine the therapeutic
effect of human WJ-MSC-CM in wound healing on patients with chronic skin ulcer.
Phase:
Phase 1
Details
Lead Sponsor:
Sukma Skin Treatment
Collaborators:
PT Pharma Metric Labs PT. Pharma Metric Labs Stem Cell and Cancer Institute, Kalbe Farma Tbk